Immune-Boosting drug tested to shield vulnerable dialysis patients from COVID-19
NCT ID NCT04428008
Summary
This study tested whether a drug called thymalfasin (Ta1) could help prevent COVID-19 infections in people with kidney failure who receive regular dialysis. These patients are at very high risk for severe illness. Researchers gave 262 participants injections of Ta1, which is designed to boost the immune system, to see if it reduced their chances of catching COVID-19 or made infections less severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Consultants
Kansas City, Kansas, 64111, United States
Conditions
Explore the condition pages connected to this study.